<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38225804</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>153</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Vaccine Effectiveness Against Long COVID in Children.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e2023064446</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2023-064446</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective cohort study used data from 17 health systems in the RECOVER PCORnet electronic health record program for visits after vaccine availability. We examined both probable (symptom-based) and diagnosed long COVID after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The vaccination rate was 67% in the cohort of 1&#x2009;037&#x2009;936 children. The incidence of probable long COVID was 4.5% among patients with COVID-19, whereas diagnosed long COVID was 0.8%. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5-44.7) against probable long COVID and 41.7% (15.0-60.0) against diagnosed long COVID. VE was higher for adolescents (50.3% [36.6-61.0]) than children aged 5 to 11 (23.8% [4.9-39.0]). VE was higher at 6 months (61.4% [51.0-69.6]) but decreased to 10.6% (-26.8% to 37.0%) at 18-months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This large retrospective study shows moderate protective effect of severe acute respiratory coronavirus 2 vaccination against long COVID. The effect is stronger in adolescents, who have higher risk of long COVID, and wanes over time. Understanding VE mechanism against long COVID requires more study, including electronic health record sources and prospective data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Razzaghi</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirabayashi</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Andrea J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bunnell</LastName><ForeName>H Timothy</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, Delaware.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrischilles</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowell</LastName><ForeName>Lindsay G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Peter O'Donnell Jr School of Public Health; Department of Immunology, School of Biomedical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>Mollie R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>College of Nursing, University of Utah, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanauer</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Learning Health Sciences, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higginbotham</LastName><ForeName>Miranda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horne</LastName><ForeName>Benjamin D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Intermountain Heart Institute, Intermountain Health, Salt Lake City, Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Carol R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York City, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishkin</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naggie</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Duke University School of Medicine, Duke Clinical Research Institute, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajor</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paranjape</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwenk</LastName><ForeName>Hayden T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Stanford School of Medicine, Palo Alto, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sills</LastName><ForeName>Marion R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>OCHIN, Inc, Portland, Oregon.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedla</LastName><ForeName>Yacob G</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>L Charles</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECOVER CONSORTIUM</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2023 Sep 28:2023.09.27.23296100. doi: 10.1101/2023.09.27.23296100</RefSource><PMID Version="1">37808803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>CONFLICT OF INTEREST DISCLOSURES:</b> Dr Cummins is employed by Doxy.me Inc, a commercial telemedicine platform provider; Dr Horne is a member of the advisory boards of Opsis Health and Lab Me Analytics, and a consultant to Pfizer (regarding clinical risk scores; funds paid to Intermountain); Dr Naggie reports research grants from Gilead Sciences and AbbVie, scientific advisor/stock options from Vir Biotechnologies, consulting with no financial payment from Pardes Biosciences and Silverback Therapeutics, DSMB fees from Personal Health Insights, Inc, event adjudication committee fees from BMS/PRA outside the submitted work; Dr Mishkin receives Grant support from Pfizer paid directly to Institution Advisory Board for Takeda; Dr Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society; Dr Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris; and the remaining authors have no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>16</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38225804</ArticleId><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="doi">10.1542/peds.2023-064446</ArticleId><ArticleId IdType="pii">196419</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Johns Hopkins University. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available at: https://coronavirus.jhu.edu/map.html. Accessed March 4, 2023</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). CDC COVID data tracker. Available at: https://covid.cdc.gov/covid-data-tracker/. Accessed March 4, 2023</Citation></Reference><Reference><Citation>Forrest&#x2008;CB, Burrows&#x2008;EK, Mejias&#x2008;A, et al. . Severity of acute covid-19 in children &lt;18 years old March 2020 to December 2021. Pediatrics. 2022;149(4):e2021055765.</Citation><ArticleIdList><ArticleId IdType="pubmed">35322270</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto Pereira&#x2008;SM, Nugawela&#x2008;MD, Rojas&#x2008;NK, et al. . Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people. Arch Dis Child. 2023;108(4):289&#x2013;295</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10086284</ArticleId><ArticleId IdType="pubmed">36599625</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani&#x2008;G, Verlato&#x2008;G, Bertino&#x2008;E, et al. . Long COVID-19 in children: an Italian cohort study. Ital J Pediatr. 2022;48(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163526</ArticleId><ArticleId IdType="pubmed">35659358</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis&#x2008;HE, McCorkell&#x2008;L, Vogel&#x2008;JM, Topol&#x2008;EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuczborska&#x2008;K, Buda&#x2008;P, Ksi&#x105;&#x17c;yk&#x2008;J. Long-COVID in immunocompromised children. Eur J Pediatr. 2022;181(9):3501&#x2013;3509</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9281224</ArticleId><ArticleId IdType="pubmed">35834042</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce&#x2008;CA, Herold&#x2008;KC, Herold&#x2008;BC, et al. . COVID-19 and children. Science. 2022;377(6611):1144&#x2013;1149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10324476</ArticleId><ArticleId IdType="pubmed">36074833</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy&#x2008;EJ, Nakra&#x2008;N, Gale&#x2008;C, Dimitriades&#x2008;VR, Lakshminrusimha&#x2008;S. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management. Pediatr Res. 2023;93(6):1499&#x2013;1508</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436161</ArticleId><ArticleId IdType="pubmed">36050390</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard&#x2008;F, Perego&#x2008;E. How and why patients made long Covid. Soc Sci Med. 2021;268:113426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Riphagen&#x2008;S, Gomez&#x2008;X, Gonzalez-Martinez&#x2008;C, Wilkinson&#x2008;N, Theocharis&#x2008;P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607&#x2013;1608</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7204765</ArticleId><ArticleId IdType="pubmed">32386565</ArticleId></ArticleIdList></Reference><Reference><Citation>Say&#x2008;D, Crawford&#x2008;N, McNab&#x2008;S, Wurzel&#x2008;D, Steer&#x2008;A, Tosif&#x2008;S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc Health. 2021;5(6):e22&#x2013;e23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8057863</ArticleId><ArticleId IdType="pubmed">33891880</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi&#x2008;B, Sudry&#x2008;T, Flaks-Manov&#x2008;N, et al. . Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao&#x2008;S, Lee&#x2008;GM, Razzaghi&#x2008;H, et al. . Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. JAMA Pediatr. 2022;176(10):1000&#x2013;1009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Adler&#x2008;L, Israel&#x2008;M, Yehoshua&#x2008;I, et al. . Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study. BMJ Open. 2023;13(2):e064155</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9944622</ArticleId><ArticleId IdType="pubmed">36810170</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk&#x2008;AL, Kuppermann&#x2008;N, Florin&#x2008;TA, et al. ; Pediatric Emergency Research Network&#x2013;COVID-19 Study Team. Post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection. JAMA Netw Open. 2022;5(7):e2223253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308058</ArticleId><ArticleId IdType="pubmed">35867061</ArticleId></ArticleIdList></Reference><Reference><Citation>Katika&#x2008;A, Zoulias&#x2008;E, Koufi&#x2008;V, Malamateniou&#x2008;F. Mining Greek tweets on long COVID using sentiment analysis and topic modeling. Stud Health Technol Inform. 2023;305:545&#x2013;548</Citation><ArticleIdList><ArticleId IdType="pubmed">37387088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasi&#x2008;SG, Dhir&#x2008;SK, Shah&#x2008;A, et al. ; Advisory Committee on Vaccines and Immunization Practices (ACVIP), Indian Academy of Pediatrics. Coronavirus disease 2019 (COVID-19) vaccination for children: position statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices. Indian Pediatr. 2022;59(1):51&#x2013;57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8821846</ArticleId><ArticleId IdType="pubmed">34927603</ArticleId></ArticleIdList></Reference><Reference><Citation>Barie&#x2008;PS, Brindle&#x2008;ME, Khadaroo&#x2008;RG, Klassen&#x2008;TL, Huston&#x2008;JM. Omicron, long-COVID, and the safety of elective surgery for adults and children: joint guidance from the Therapeutics and Guidelines Committee of the Surgical Infection Society and the Surgery Strategic Clinical Network, Alberta Health Services. Surg Infect (Larchmt). 2023;24(1):6&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pubmed">36580648</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul&#x2008;S, Mishra&#x2008;CM. Do we need to vaccinate every child against COVID-19: what evidence suggests-a systematic review of opinions. Front Public Health. 2022;10:1002992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9679503</ArticleId><ArticleId IdType="pubmed">36424958</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden&#x2008;LR, El Sahly&#x2008;HM, Essink&#x2008;B, et al. ; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403&#x2013;416</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>El Sahly&#x2008;HM, Baden&#x2008;LR, Essink&#x2008;B, et al. ; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774&#x2013;1785</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482810</ArticleId><ArticleId IdType="pubmed">34551225</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas&#x2008;SJ, Moreira&#x2008;EDJr, Kitchin&#x2008;N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761&#x2013;1773</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott&#x2008;P, Haw&#x2008;D, Wang&#x2008;H, et al. ; COVID-19 Genomics UK (COG-UK) Consortium. Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the delta variant. Science. 2021;374(6574):eabl9551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763627</ArticleId><ArticleId IdType="pubmed">34726481</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray&#x2008;G, Collie&#x2008;S, Goga&#x2008;A, et al. . Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa. N Engl J Med. 2022;386(23):2243&#x2013;2245</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9093716</ArticleId><ArticleId IdType="pubmed">35507482</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng&#x2008;HF, Ackerson&#x2008;BK, Luo&#x2008;Y, et al. . Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022;28(5):1063&#x2013;1071</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9117141</ArticleId><ArticleId IdType="pubmed">35189624</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly&#x2008;Z, Bowe&#x2008;B, Xie&#x2008;Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461&#x2013;1467</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock&#x2008;MD, Chew&#x2008;RF, Preiss&#x2008;AJ, et al. ; N3C; RECOVER Consortia. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun. 2023;14(1):2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet&#x2008;M, Dercon&#x2008;Q, Harrison&#x2008;PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154&#x2013;162</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013695</ArticleId><ArticleId IdType="pubmed">35447302</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani&#x2008;D, Bermingham&#x2008;C, Pouwels&#x2008;KB, et al. . Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte&#x2008;KI, Catahay&#x2008;JA, Velasco&#x2008;JV, et al. . Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine. 2022;53:101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun&#x2008;MC, Singh&#x2008;AK, Pal&#x2008;D, et al. . Characteristics and predictors of Long COVID among diagnosed cases of COVID-19. PLoS One. 2022;17(12):e0278825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg&#x2008;E, Han&#x2008;AX, Boyd&#x2008;A, et al. ; RECoVERED Study Group. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine. 2022;40(32):4424&#x2013;4431</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein&#x2008;NP, Demarco&#x2008;M, Fleming-Dutra&#x2008;KE, et al. . Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. Pediatrics. 2023;151(5):e2022060894.</Citation><ArticleIdList><ArticleId IdType="pubmed">37026401</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention (CDC). Long COVID or post-COVID conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Accessed October 10, 2023</Citation></Reference><Reference><Citation>Lorman&#x2008;V, Rao&#x2008;S, Jhaveri&#x2008;R, et al. . Understanding pediatric long COVID using a tree-based scan statistic approach: an EHR-based cohort study from the RECOVER Program. JAMIA Open. 2023;6(1):ooad016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10013630</ArticleId><ArticleId IdType="pubmed">36926600</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Data definitions for COVID-19 vaccinations in the United States. Accessed August 25, 2022</Citation></Reference><Reference><Citation>
Gonzalez-Barrera&#x2008;A, Lopez&#x2008;MH. Is being Hispanic a matter of race, ethnicity or both?. Available at: https://www.pewresearch.org/short-reads/2015/06/15/is-being-hispanic-a-matter-of-race-ethnicity-or-both/. Accessed October 12, 2023</Citation></Reference><Reference><Citation>Khullar&#x2008;D, Zhang&#x2008;Y, Zang&#x2008;C, et al. . Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: an EHR-based cohort study from the RECOVER program. J Gen Intern Med. 2023;38(5):1127&#x2013;1136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933823</ArticleId><ArticleId IdType="pubmed">36795327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff&#x2008;ER, Madlock-Brown&#x2008;C, Baratta&#x2008;JM, et al. ; N3C Consortium; RECOVER Consortium. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21(1):58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon&#x2008;TD,, Haaland&#x2008;W,, Hawley&#x2008;K,, Lambka&#x2008;K,, Mangione-Smith&#x2008;R. Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 3.0.&#xa0;Acad Pediatr. 2018;18(5):577&#x2013;580</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahai&#x2008;H, Khurshid&#x2008;A. Statistics in Epidemiology: Methods, Techniques, and Applications. CRC Press; 1996</Citation></Reference><Reference><Citation>Ho&#x2008;D, Imai&#x2008;K, King&#x2008;G, Stuart&#x2008;EA. MatchIt: nonparametric preprocessing for parametric causal inference. Journal of Statistical Software. 2011;42(8):1&#x2013;28</Citation></Reference><Reference><Citation>
Ridgeway&#x2008;GM, McCaffrey&#x2008;DF, Morral&#x2008;AR, Cefalu&#x2008;M, Burgette&#x2008;LF, Pane&#x2008;JD, Griffin&#x2008;BA. Toolkit for weighting and analysis of nonequivalent groups: a tutorial for the R TWANG package. Available at: https://www.rand.org/pubs/tools/TLA570-5.html. Accessed October 29, 2023</Citation></Reference><Reference><Citation>
Therneau&#x2008;TM. A package for survival analysis in R. Available at: https://cran.r-project.org/package=survival. Accessed August 7, 2023</Citation></Reference><Reference><Citation>Fowlkes&#x2008;AL, Yoon&#x2008;SK, Lutrick&#x2008;K, et al. . Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - PROTECT cohort, July 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(11):422&#x2013;428</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942308</ArticleId><ArticleId IdType="pubmed">35298453</ArticleId></ArticleIdList></Reference><Reference><Citation>Yewdell&#x2008;JW. Individuals cannot rely on COVID-19 herd immunity: durable immunity to viral disease is limited to viruses with obligate viremic spread. PLoS Pathog. 2021;17(4):e1009509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075217</ArticleId><ArticleId IdType="pubmed">33901246</ArticleId></ArticleIdList></Reference><Reference><Citation>Price&#x2008;AM, Olson&#x2008;SM, Newhams&#x2008;MM, et al. ; Overcoming Covid-19 Investigators. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med. 2022;386(20):1899&#x2013;1909</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006785</ArticleId><ArticleId IdType="pubmed">35353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan&#x2008;SHX, Cook&#x2008;AR, Heng&#x2008;D, Ong&#x2008;B, Lye&#x2008;DC, Tan&#x2008;KB. Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age. N Engl J Med. 2022;387(6):525&#x2013;532</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9342421</ArticleId><ArticleId IdType="pubmed">35857701</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch&#x2008;M, Krammer&#x2008;F, Regev-Yochay&#x2008;G, Lustig&#x2008;Y, Balicer&#x2008;RD. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22(1):57&#x2013;65</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan&#x2008;SG, Tchetgen Tchetgen&#x2008;EJ, Cowling&#x2008;BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184(5):345&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013887</ArticleId><ArticleId IdType="pubmed">27587721</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch&#x2008;M, Jha&#x2008;A, Simonsen&#x2008;L. Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies. Int J Epidemiol. 2016;45(6):2060&#x2013;2074</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841615</ArticleId><ArticleId IdType="pubmed">27453361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>